Xponance’s Apogee Therapeutics APGE Stock Holding History

Xponance’s Portfolio APGE Stock Details APGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$586K	Buy	4,414 +681	+18%	+$61.4K	﹤0.01%	1031
2026 Q1	$314K	Buy	3,733 +718	+24%	+$52.1K	﹤0.01%	1245
2025 Q4	$228K	Buy	+3,015	New	+$190K	﹤0.01%	1323

Other funds holding APGE

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

Xponance's APGE Position: Q2 2026 in Review

Xponance increased its Apogee Therapeutics (APGE) stake by 18% in Q2 2026, buying an estimated $61.4K and bringing the position to 4,414 shares worth $586K. The position accounts for ﹤0.01% of the portfolio, ranked #1031.

Xponance first reported a position in APGE in Q4 2025 and has held it in 3 quarters since. 289 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

Xponance held 4,414 shares of Apogee Therapeutics worth $586K as of Q2 2026.
Xponance bought 681 Apogee Therapeutics shares in Q2 2026, an estimated $61.4K.
Apogee Therapeutics made up ﹤0.01% of Xponance's portfolio in Q2 2026, its #1031 holding.
Xponance first reported a position in Apogee Therapeutics in Q4 2025 and has held it in 3 quarters since.
289 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on Xponance's 13F filing for Q2 2026, filed 10 Aug 2026.